In short
Ertugliflozin is a medication being studied for its effects on type 2 diabetes and heart conditions. Clinical trials are investigating how it impacts blood sugar levels, heart function, and other health measures in different patient groups. This article summarizes key findings from recent ertugliflozin clinical trials.
At a glance
- Primary Conditions Studied
- Type 2 Diabetes Mellitus, Heart Failure, Left Ventricular Dysfunction
- Key Dosages
- Ranging from 1 mg to 25 mg daily, with some studies testing up to 100 mg
- Main Outcome Measures
- Blood glucose control, heart function parameters, kidney function, body weight
- Imaging Techniques Used
- Cardiac MRI, Echocardiography
- Notable Biomarkers
- NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
- Study Designs
- Randomized controlled trials, dose-escalation studies, pharmacokinetic studies
- Patient Populations
- Diabetic patients, heart failure patients, healthy volunteers
- Unique Applications
- Potential effects on cardiac fibrosis, mitral regurgitation
- Safety Assessments
- Adverse event monitoring, tolerability evaluations
- Duration of Studies
- Ranging from single-dose studies to 48-week trials
What is Ertugliflozin?
Ertugliflozin is a medication used primarily for the treatment of type 2 diabetes mellitus. It is also known by the brand name Steglatro and may be referred to by its research codes PF-04971729 or MK-8835. Ertugliflozin belongs to a class of drugs called sodium-glucose co-transporter-2 (SGLT2) inhibitors.
How Does Ertugliflozin Work?
Ertugliflozin works by blocking the action of a protein in your kidneys called SGLT2. This protein normally helps your body reabsorb glucose (sugar) from your urine back into your bloodstream. By inhibiting SGLT2, ertugliflozin causes more glucose to be excreted in your urine, which helps lower blood sugar levels.
This mechanism of action not only helps control blood sugar but also has some additional effects that researchers are studying. These include potential benefits for heart health and body weight.
What Conditions Does Ertugliflozin Treat?
Ertugliflozin is primarily used to treat:
- Type 2 Diabetes Mellitus: This is the main condition for which ertugliflozin is prescribed. It helps control blood sugar levels in adults with type 2 diabetes.
- Heart Failure: Recent research suggests that ertugliflozin may also be beneficial for patients with heart failure, particularly those with reduced ejection fraction (HFrEF). This is a condition where the heart muscle doesn't pump blood as well as it should.
- Cardiovascular Disease: Studies are investigating the potential benefits of ertugliflozin in reducing the risk of cardiovascular events in patients with type 2 diabetes who also have cardiovascular disease.
Dosage and Administration
Ertugliflozin is typically taken orally (by mouth) once daily. The usual starting dose is 5 mg, but this can vary depending on the individual patient and their condition. In some studies, doses up to 15 mg per day have been used.
It's important to take ertugliflozin exactly as prescribed by your doctor. The medication can be taken with or without food. If you're also taking insulin or medications that increase insulin production, your doctor may adjust these doses to reduce the risk of low blood sugar.
Potential Side Effects
Like all medications, ertugliflozin can cause side effects. Common side effects may include:
- Increased urination
- Thirst
- Genital yeast infections
- Urinary tract infections
- Changes in blood lipid levels
More serious side effects, though rare, can include diabetic ketoacidosis (a dangerous condition where the body produces high levels of blood acids called ketones) and kidney problems. It's important to discuss all potential side effects with your healthcare provider.
Ongoing Research and Potential New Uses
Researchers are currently studying ertugliflozin for several potential new uses:
- Heart Failure Treatment: Studies are investigating how ertugliflozin affects heart function in patients with heart failure. This includes looking at its effects on the heart's ability to pump blood effectively and on fluid retention in the body.
- Mitral Valve Regurgitation: This is a condition where the heart's mitral valve doesn't close properly, allowing blood to flow backward in the heart. A study is examining whether ertugliflozin can help reduce the severity of this condition.
- Effects on Body Fat: Researchers are studying how ertugliflozin affects different types of body fat, including fat around the heart (epicardial fat). This could provide insights into how the drug affects cardiovascular health.
- Cardiac Fibrosis: This refers to the formation of scar tissue in the heart. A study is looking at whether ertugliflozin can help reduce cardiac fibrosis in patients with heart failure.
These ongoing studies may lead to new approved uses for ertugliflozin in the future, potentially benefiting a wider range of patients.